Skip to main content
x

Recent articles

ESMO 2024 – Scorpion joins Relay in the alpha club

What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

ESMO 2024 – J&J eyes Rybrevant colorectal expansion

Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.

ESMO 2024 – changing FDA stance could haunt Astra’s Niagara win

Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?

ESMO 2024 – Keytruda/Lenvima leap... up to a point

Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.

ESMO 2024 – a role for immunotherapy in ovarian cancer

If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.

ESMO 2024 – combos could be the way forward for CDK2

Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.

Most Popular